Related Experiment Video
Updated: Jan 18, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
LRG1 in cancer: mechanisms, potential therapeutic target, and use in clinical diagnosis
Federico Osorio-Antonio1,2, Daniela Michel Diaz-González3, Elizabeth Bautista-Rodríguez4,5
1Children's Hospital of Tlaxcala, Tlaxcala, 90610, Mexico.
Abstract:
Leucine-rich alpha-2 glycoprotein 1 (LRG1) is an extracellular protein whose elevated expression has been linked to cancers with poor prognosis and low survival rates. Given its significance as a biomarker, this manuscript explores the role of LRG1 in cancer, as several studies have identified it as a promoter of proliferation, angiogenesis, invasion, and metastasis in breast, ovarian, pancreatic, and neuroblastoma cancers. However, contrasting evidence suggests that LRG1 inhibits proliferation in hepatocellular carcinoma cells and suppresses migration and invasion in esophageal squamous cell carcinoma. We also examine its regulation and the associated signaling pathways, including TGF-β and PI3K/AKT/mTOR.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
